MAMehmet Aslan

Mehmet Aslan

*This is an algorithmically generated author record based on publicly available information.

Mehmet Aslan has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Primary spinal extramedullary diffuse large B–cell lymphoma presenting with initial spinal cord compression: A case report

    by Ömer Candar, Ömer Ekinci, Ali Doğan, Mehmet Aslan, İbRahim Aras, Cengiz Demir

    Extranodal lymphomas, by definition, can involve any organ or tissue. Brain parenchyma, spinal cord, eyes, cranial nerves, and meninx are extranodal regions that show involvement at much lower rates. Primary central nervous system (CNS) lymphomas comprise 4% of all brain tumors and 4–6% of extranodal lymphomas. It is quite rare for lymphoma patients to present to the hospital with symptoms and findings associated with spinal cord compression as the initial presentation. This condition can lead to irreversible autonomic dysfunction, and motor and sensory loss. Here, we present a rare primary spinal intradural extramedullary diffuse large B–cell lymphoma (DLBCL) case who presented with acute neurological symptoms and no findings of cerebral involvement or involvement at any other site. MRI was performed for the spinal region. The surgical procedure was performed for the detected mass. Immunohistochemical staining of the excised mass was performed. In the surgical operation, the mass showed partial invasion of the vertebral bone and the surrounding muscle. Considering the rapid progression of the neurological deficit, surgical resection was performed primarily for spinal decompression. Subsequently, 6 courses of R–CHOP chemotherapy regimen were given for the residual tissue, and radiotherapy was administered to the involved region. Timely and effective treatment achieved a complete recovery of motor and sensory function. The patient remains in complete remission without clinical or radiological relapse under follow-up after nearly 4 years. Isolated MS is a rare hematologic neoplasia comprised of immature granulocytic cells. Although it can be detected in any part of the body, hepatobiliary, and particularly, pancreatic involvement is much less frequent. The optimal treatment of the disease is not elucidated due to the lack of relevant data and large prospective studies in the literature. The most recommended treatments are the systemic chemotherapies used in AML remission induction treatment. The authors think that alloHSCT must be considered after the induction of remission in MS, as it offers an advantage in terms of overall survival and leukemia–free survival.

  • Isolated myeloid sarcoma causing obstructive jaundice in duodenal ampulla: a very rare case

    by Ömer Candar, Ömer Ekinci, Mustafa Merter, Mehmet Aslan, İlKnur Çalık

    Isolated myeloid sarcoma (MS) is a malignant neoplasm of myeloid origin that is located in extramedullary tissues. MS is rare; only 5–6% of MS cases originate from the gastrointestinal tract (GIT). These patients usually present with non–specific symptoms associated with the GIT, thus, the diagnosis is easily overlooked and patients are misdiagnosed. Established treatment options for MS include local therapies (surgery or radiotherapy or a combination), systemic chemotherapy, allogeneic hematopoietic stem–cell transplantation (HSCT), and targeted therapies. In this article, we present a case of isolated MS localized in the duodenal ampulla that presented with cholestatic jaundice. On magnetic resonance imaging (MRI) and MR cholangiography (MRCP), a 3.8×3.5 cm mass lesion was visualized in the duodenal ampulla. A diagnosis of MS was made based on an endoscopic retrograde cholangiopancreatography biopsy. It was recognized as an isolated MS after further examination. An idarubicin and cytarabine–based chemotherapy regimen were administered for induction and allogeneic HSCT was administered as post–remission consolidation therapy. The patient remains in remission under follow–up in the 6th month after allogeneic HSCT. Isolated MS is a rare hematologic neoplasia comprised of immature granulocytic cells. Although it can be detected in any part of the body, hepatobiliary, and particularly, pancreatic involvement is much less frequent. The optimal treatment of the disease is not elucidated due to the lack of relevant data and large prospective studies in the literature. The most recommended treatments are the systemic chemotherapies used in AML remission induction treatment. The authors think that allogeneic HSCT must be considered after the induction of remission in MS, as it offers an advantage in terms of overall survival and leukemia–free survival.